Nystatin is commonly prescribed as prophylaxis in children beyond the neonatal age.

The indications for nystatin as prophylaxis or treatment are limited. In the PASOAP (Paediatric Antifungal Stewardship Optimising Antifungal Prescription) study, a high use of nystatin in hospitalised children beyond the neonatal age was observed. In this report we present the data on nystatin use in infants and children ≥ 3 months who participated in the PASOAP study. Nystatin was prescribed mainly for prophylaxis. Congenital heart disease, cystic fibrosis and chronic renal disease were the most commonly reported conditions in children receiving prophylactic nystatin. There is sparse evidence supporting the use of nystatin prophylaxis beyond neonates; trials in specific paediatric patient groups are required.